OTCQB: MYDX Investor Summary 2016

MyDx, Inc. (OTCQB: MYDX) is a science and technology company that produces and markets the first battery operated, multi-use handheld chemical analyzer for consumers. Its patented MyDx™ (My Diagnostic) product line is comprised of the MyDx device that connects via Bluetooth to a smart phone app to analyze the chemical effect of what consumers eat, drink and inhale (see: www.cdxlife.com/cdxshop).

The San Diego-based Company launched its first product sensor, CannaDxTM, in late 2015 to address the explosive growth in the cannabis market and enable consumers to affordably identify the chemical composition of cannabis at the point of care. A June 2015 study in the Journal of the American Medical Association of 75 edible cannabis products sold found 83% of them mislabeled the THC content. MyDx also has three new sensors in its commercialization pipeline for analyzing pesticides in food, chemicals in water, and toxins in the air.

MyDx expects to reach profitability in 2016. The MyDx analyzer retails for $699 and includes the hardware (analyzer and sensor), smart phone app and one-time disposable inserts. It is multi-use and houses interchangeable sensors for different applications (cannabis, water, food, air). By connecting to its Android or iOS smartphone MyDx app, it leverages a crowd-sourced cloud-based database. US sales are expected to jump as its first major distribution deal takes effect in the current quarter. Global sales are diverse and exceeding estimates.

The Analyzer has a blended gross margin starting at about 50% and is expected to scale with higher volumes the Company is now preparing to manufacture. The MyDx Analyzer requires one-time use “sample inserts,” that are priced at $1.29 and provide a recurring revenue stream with gross margins of approximately 80%. Additionally, the Company generates revenue on premium warranties and other ancillary sales.

Goals and Catalysts for Exponentially Increasing Earnings Power include:

1) CannaDX: The US cannabis testing market is forecast to reach $800 to $900 million by 2020

2) Major Nanolux Tech – CannaDx distribution deal (targets growers) signed Q2 valued at $4M+

3) Upgraded manufacturing and supply chain

4) Launch three new sensors that address different, multi-billion dollar global markets

5) Steep revenue ramp starting Q3-16

6) Numerous US States have ballot initiatives to legalize medical or recreational pot in November

7) Led by CEO Daniel Yazbeck, former Pfizer Scientist and Market Developer to Panasonic.


Tags: , , , , ,

No comments yet.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: